Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
UK Economy Grows 0.4% in July, Beating Forecasts 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
US Treasury Yields Near 5% as Oil Fuels Inflation Fears 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
U.S. Issues Cuba Health Alert as Illnesses Rise 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
OpenAI Targets Specialized Industries as Enterprise AI Demand Grows 
Add as a preferred source on Google
South Korea’s JW Pharmaceutical has received a patent in Russia for a hair loss treatment currently under development, marking the first time that its candidate drug has been patented overseas.
The pharmaceutical firm received a patent for JW0061, its Wnt-targeted hair loss treatment, from Russia's Federal Service for Intellectual Property.
The patent covers a new heterocyclic inducer of the Wnt signaling pathway, including its base or isomer, and compositions containing it as an active ingredient.
JW has also submitted patent applications in more than ten nations, including the US, EU, Japan, and China.
JW0061 exhibits a novel method of action by directly binding to the GFRA1 protein in human hair dermal papilla cells, activating the Wnt signaling pathway. This is the first instance of a low-molecular-weight medication that describes the mechanism of hair growth that has been documented.
JW is now evaluating non-clinical toxicity in accordance with good laboratory practice with the intention of initiating clinical trials for JW0061 in the first half of 2024. Additionally, it collaborates on research projects with eminent dermatologists in the US.
JW plans to develop JW0061 as a new innovative drug that supplements or replaces existing hair loss treatments.
